Your browser doesn't support javascript.
loading
Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study.
Morata Ruiz, Laura; Ruggieri, Alessandro; Falcone, Marco; Pasquau Liaño, Juan; Gentile, Ivan; Salavert Lletí, Miguel; Moreno Núñez, Leonor; Cascio, Antonio; Tascini, Carlo; Loeches Yagüe, Maria; De Rosa, Francesco Giuseppe; Ori, Alessandra; Comandini, Alessandro; Cattaneo, Agnese; Grossi, Paolo Antonio.
Afiliación
  • Morata Ruiz L; Hospital Clìnic, Department of Infectious Diseases, University of Barcelona, Barcelona, Spain.
  • Ruggieri A; GMD, Angelini SpA, Rome, Italy. Electronic address: alessandro.ruggieri@angelinipharma.com.
  • Falcone M; AOU Pisana PO Cisanello, UO Malattie Infettive, University of Pisa, Pisa, Italy.
  • Pasquau Liaño J; Hospital Universitario Virgen de las Nieve, Unidad de Enfermedades Infecciosas, Granada, Spain.
  • Gentile I; AOU Federico II, Malattie Infettive, Patologia Clinica e Medicina Interna, Università di Napoli Federico II, Naples, Italy.
  • Salavert Lletí M; Hospital Universitario y Politécnico La Fe, Unidad de Enfermedades Infecciosas, Valencia, Spain.
  • Moreno Núñez L; Hospital Universitario Fundación Alcorcón, Enfermedades Infecciosas, Madrid, Spain.
  • Cascio A; AOU Policlinico Giaccone, UOC Malattie Infettive e Tropicali, Palermo, Italy.
  • Tascini C; ASUFC, SOC Clinica Malattie Infettive, Udine, Italy.
  • Loeches Yagüe M; Hospital Universitario La Paz, Enfermedades Infecciosas, Madrid, Spain.
  • De Rosa FG; Ospedale Cardinal Massaia, SC Malattie Infettive, Asti, Italy, AOU Città della Salute e Scienza, Presidio Molinette, Turin, Italy.
  • Ori A; Medineos Observational Research - IQVIA, Modena, Italy.
  • Comandini A; GMD, Angelini SpA, Rome, Italy.
  • Cattaneo A; GMD, Angelini SpA, Rome, Italy.
  • Grossi PA; ASST Sette Laghi, SC Malattie Infettive e Tropicali, University of Insubria, Varese, Italy.
J Glob Antimicrob Resist ; 36: 200-209, 2024 03.
Article en En | MEDLINE | ID: mdl-38211660
ABSTRACT

OBJECTIVES:

To retrospectively describe the patterns of use of dalbavancin for treating infections in diabetic patients in Italian and Spanish standard clinical practice.

METHODS:

DALBADIA [NCT04959799] was a multicentre, observational, retrospective cohort study, conducted in Italy and Spain. The study enrolled 97 adults with type 1 or 2 diabetes mellitus, treated with dalbavancin as per standard clinical practice for a Gram-positive bacterial infection or the Gram-positive component of a mixed infection.

RESULTS:

Dalbavancin was used to treat cellulitis (18/92 patients, 19.6%), followed by prosthetic joint infection (14 patients, 15.2%), endocarditis (13 patients, 14.1%), and primary bacteraemia (10 patients, 10.9%); 78/92 (84.8%) patients had Gram-positive infections only, and 14 (15.2%) had mixed infections. The most frequently isolated microorganisms were Staphylococcus aureus in 43 (55.8% of the patients with microbial isolation), 25.6% of which methicillin-resistant; Staphylococcus epidermidis in 13 (16.9%), 53.8% of which methicillin-resistant; Enterococcus faecalis in 11 (14.3%). The main reason for the dalbavancin choice was the intent to simplify the antibiotic regimen (81.5% of cases). A multidisciplinary team participated in the treatment choice process for 53 (57.6%) patients. Dalbavancin was given as first-line antibiotic in 34 (37.0%) patients and administered as one infusion in 32 (34.8%), and as two infusions in 39 (42.4%). In total, 57/62 (91.9%) eligible patients with available assessment were judged clinically cured or improved at the end of observation.

CONCLUSION:

In clinical practice, dalbavancin was used in diabetic patients to treat ABSSSIs and other difficult-to-treat infections with a favourable safety profile and a high rate of positive clinical responses.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Teicoplanina / Diabetes Mellitus / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies Límite: Adult / Humans País/Región como asunto: Europa Idioma: En Revista: J Glob Antimicrob Resist Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Teicoplanina / Diabetes Mellitus / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies Límite: Adult / Humans País/Región como asunto: Europa Idioma: En Revista: J Glob Antimicrob Resist Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos